Dr. Reddys Laboratories Ltd.

Dr Reddy’s Laboratories, country’s pharma major has decided to introduce its biosimilars in developed markets. biosimilars are used to treat patients suffering from cancer at a price that is significantly more affordable than the corresponding innovator drugs. During 2011-12, the company’s global biosimilars business earned $26 million revenue reporting 25% year-on-year growth.

Recently, the company entered into a partnership with Merck Serono, a division of Germany-based Merck KGaA, to co-develop biosimilar compounds. The collaboration was to concentrate on monoclonal antibodies (MAbs) in the oncology segment besides, manufacturing and commercialization of the compounds.